305 Results

People

  1. Seidman
    Seidman
  2. Aghajanian
    Aghajanian
  3. De Angelis
    De Angelis
  4. Hudis
    Hudis
  5. Kelsen
    Kelsen
  6. Lichtman
    Lichtman
  7. Saltz
    Saltz
  8. Scher
    Scher
  9. Bajorin
    Bajorin
  10. Fornier
    Fornier

Groups

  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)
  7. Gastrointestinal Oncology Service (37)
  8. Surgery (29)
  9. Genitourinary Oncology Service (28)
  10. Center for Pancreatic Cancer Research (26)
  1. "peripheral neuropathy"
Formats
  1. Journal Article (283)
  2. Review (10)
  3. Conference Paper (6)
  4. Correspondence (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (206)
  2. Solid Tumor Oncology Division (153)
  3. Survivorship Research (59)
  4. Hematologic Malignancies, Division of (51)
  5. Center for Hematologic Malignancies (47)
  6. Breast Medicine Service (43)

More Groups

People
  1. Andrew Seidman (16)
  2. Carol Aghajanian (12)
  3. Lisa De Angelis (12)
  4. Clifford Hudis (10)
  5. David Kelsen (10)
  6. Howard Scher (10)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (19)
  4. 2022 (11)
  5. 2021 (7)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Gynecologic Oncology (15)
  3. Lancet Oncology (14)
  4. Cancer (10)
  5. Annals of Oncology (9)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (56)
  2. American Society of Clinical Oncology (26)
  3. Elsevier Science, Inc. (25)
  4. Springer (20)
  5. Wiley Blackwell (17)
  6. Oxford University Press (15)

More Publishers

Results (305)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SOLTI NeoPARP: A phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer
    Journal Article

    Llombart-Cussac, A.; Bermejo, B.; Villanueva, C.; Delaloge, S.; Morales, S.; BalmanĖƒa, J.; Amillano, K.; Bonnefoi, H.; Casas, A.; Manso, L.; more...
    Breast Cancer Research and Treatment (2015)

    Fulltext@MSK | Save
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
    Journal Article

    Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F. S.; Schachter, J.; Pavlick, A. C.; Lewis, K. D.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • The double-edged sword: Neurotoxicity of chemotherapy
    Journal Article

    Magge, R. S.; Deangelis, L. M.
    Blood Reviews (2015)

    Fulltext@MSK | Save
  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Coleman, R. L.; Sill, M. W.; Bell-Mcguinn, K.; Aghajanian, C.; Gray, H. J.; Tewari, K. S.; Rubin, S. C.; Rutherford, T. J.; Chan, J. K.; Chen, A.; more...
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • Long-term survival after high-dose-rate brachytherapy for locally advanced or recurrent colorectal adenocarcinoma
    Journal Article

    Terezakis, S.; Morikawa, L.; Wu, A.; Zhang, Z.; Shi, W.; Weiser, M. R.; Paty, P. B.; Guillem, J.; Temple, L.; Nash, G. M.; more...
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • Emerging drugs for diffuse large B-cell lymphoma
    Journal Article

    Mondello, P.; Younes, A.
    Expert Review of Anticancer Therapy (2015)

    Fulltext@MSK | Save
  • R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
    Journal Article

    Omuro, A.; Correa, D. D.; Deangelis, L. M.; Moskowitz, C. H.; Matasar, M. J.; Kaley, T. J.; Gavrilovic, I. T.; Nolan, C.; Pentsova, E.; Grommes, C. C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)
    Journal Article

    Sikov, W. M.; Berry, D. A.; Perou, C. M.; Singh, B.; Cirrincione, C. T.; Tolaney, S. M.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E. R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Evolution of CD30 as a target in Hodgkin lymphoma, mature t-cell lymphoma, and other lymphomas
    Journal Article

    Younes, A.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save